GSK Reports Strong Q3 2025 Results with 3.36% Pre-Market Surge and Raises Full-Year Guidance

October 29, 2025British pharmaceutical giant GSK releases Q3 financial report. The data shows that GSK's Q3Sales reached 8.5 billion pounds (approximately 10.6 billion US dollars), year-on-year growth7%（At constant exchange rates+8%），Core profitability significantly improved.

Previously, GSK projected revenue growth of 3%-5% and profit growth of 6%-8%.Driven by double-digit growth in HIV and oncology drugs,Company performance exceeds market expectations, andRaise Full-Year Performance GuidanceTo 6% to 7%。

GSK stated,It turned a profit in the third quarter, while revenue grew year-on-year compared to last year.For the three months ended September 30, the profit attributable to shareholders was £2.01 billion, compared with a loss of £58 million in the same period last year.

After the earnings report was released, GSK's U.S. stocksPre-market up over 3%。

Background replyGSKQ3, Get Performance PDF

GSK stated that the performance growth was driven by the strong performance of its specialty pharmaceuticals and vaccines businesses, as well as the continued advancement of R&D investments.

From the perspective of business structure, GSK achieved breakthroughs in multiple areas in the third quarter.

• Specialty Medicines sales reached £3.4 billion, a year-on-year increase of 16%.，Respiratory, Immunology and Inflammation segment grew 15%,Oncology segment grows by 39%，Sales of HIV Treatment Drugs Increase by 12%。

• Vaccine segment records 2.7 billion pounds, a year-on-year increase of 2%, the growth of Shingrix, the herpes zoster vaccine, was 13%, and the growth of Arexvy, the respiratory syncytial virus (RSV) vaccine, was 36%.

• General Medicines business performed steadily, achieving sales of 2.5 billion pounds, a year-on-year increase of 4%.

The CEO of the company pointed out that GSK's growth momentum in core areas such as respiratory, immunology, oncology, and vaccines has laid a solid foundation for development in 2026 and the long term.

Driven by the growth of core businesses, optimization of cost structure, and reduced legal expenses, GSK’s total operating profit for this quarter doubled year-over-year. Core operating profit increased by 11% year-over-year, and core earnings per share grew by 14%. The company generated approximately £2.5 billion in cash from operating activities and around £1.2 billion in free cash flow, maintaining a consistently robust cash flow performance.

For the full year 2025, GSK has raised its guidance for sales growth to 6%-7%, core operating profit to 9%-11%, and earnings per share to 10%-12%.

Reprint/Business/Contribution| Contact WeChat15618157102（sum_Gmi）

Business Cooperation

Call for Papers

Click to learn more